Group A streptococcal vaccine - PREVENT/Vaxent

Drug Profile

Group A streptococcal vaccine - PREVENT/Vaxent

Alternative Names: GAS vaccine - PREVENT; StreptAnova®; Streptococcal A vaccine - PREVENT; Streptococcal vaccine - PREVENT/Vaxent

Latest Information Update: 26 Nov 2015

Price : $50

At a glance

  • Originator The University of Tennessee Health Science Center
  • Developer Pan-Provincial Vaccine Enterprise; Vaxent Inc.
  • Class Bacterial vaccines; Peptide vaccines; Streptococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Streptococcal infections

Most Recent Events

  • 01 Aug 2015 Phase-I clinical trials in Streptococcal infections in Canada (Parenteral) (NCT02564237)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top